Properties of Curcuma longa L. in type 2 diabetes mellitus: Integrative review
Resumo
A curcumina, componente bioativo da Curcuma Longa L., apresenta diversas propriedades biológicas e farmacológicas e sua utilização tem sido documentada no tratamento do diabetes e suas complicações. O objetivo desta revisão integrativa de literatura foi analisar a produção de literatura, de estudos randomizados sobre o efeito da cúrcuma longa, curcuminóides ou curcumina, nos parâmetros bioquímicos e antropométricos de pacientes adultos com diabetes mellitus tipo 2 (DMT2). Para o levantamento dos artigos, utilizou-se as seguintes bases de dados: Cochrane Library, Medline, Lilacs e SciELO. Após a aplicação dos critérios de elegibilidade, nove artigos publicados entre 2012 e 2019 contemplaram a questão norteadora do estudo. Os resultados da análise demonstraram evidências dos benefícios da utilização da Cúrcuma longa L em pó, curcuminóides e curcumina, como adjuvante no tratamento de pacientes com DMT2, devido ao seu efeito antioxidante e melhora no perfil lipídico, glicêmico e nos parâmetros antropométricos, peso e índice de massa corporal.
Referências
-Abd El-Kader, S. M.; Al-Jiffri, O. H. Impact of weight reduction on insulin resistance, adhesive molecules and adipokines dysregulation among obese type 2 diabetic patients. African Health Sciences. Vol. 18. Num. 4. 2018. p. 873-883.
-Abdollahi, E.; e colaboradores. Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: a nature-made jack-of-all-trades? Journal of Cellular Physiology. Vol. 233. Num. 2. 2017. p.830-848.
-Abrahams, S.; e colaboradores. Antioxidant effects of curcumin in models of neurodegeneration, aging, oxidative and nitrosative stress: a review. Neuroscience. Vol. 406. 2019. p. 1-21.
-Adab, Z.; e colaboradores. Effect of turmeric on glycemic status, lipid profile, hs-CRP, and total antioxidant capacity in hyperlipidemic type 2 diabetes mellitus patients. Phytotherapy Research. Vol. 33. Num. 4. 2019. p. 1173-1181.
-Adibian, M.; e colaboradores. The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Phytotherapy Research. Vol. 33. Num. 5. 2019. p. 1374-1383.
-American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. Vol. 37. Num. Suppl.1. 2014. p. S81-S90.
-Asadi, S.; e colaboradores. Nano curcumin supplementation reduced the severity of diabetic sensorimotor polyneuropathy in patients with type 2 diabetes mellitus: a randomized double-blind placebo- controlled clinical trial. Complementary Therapies in Medicine. Vol. 43. 2019. p. 253-260.
-Austin, M. A.; e colaboradores. Low-Density Lipoprotein subclass patterns and risk of myocardial infarction. JAMA: The Journal of the American Medical Association. Vol. 260. Num. 13. 1988. p. 1917-1921.
-Basnet, P.; Skalko-Basnet, N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules. Vol. 16. Num. 6. 2011. p. 4567-4598.
-Baynes, J. W. Role of oxidative stress in development of complications in diabetes. Diabetes. Vol. 40. Num. 4. 1991. p. 405-412.
-Bonnes-Taourel, D.; Guérin, M. C.; Torreilles, J. Is malonaldehyde a valuable indicator of lipid peroxidation? Biochemical Pharmacology. Vol. 44. Num. 5. 1992. p. 985-988.
-Calles-Escandon, J.; Cipolla, M. Diabetes and endothelial dysfunction: a clinical perspective. Endocrine Reviews. Vol. 22. Num. 1. 2001. p. 36-52.
-Carmena, R. Type 2 diabetes, dyslipidemia, and vascular risk: Rationale and evidence for correcting the lipid imbalance. American Heart Journal. Vol. 150. Num. 5. 2005. p. 859-870.
-Castro, S. H.; Matos, H. J.; Gomes, M. D. B. Parâmetros antropométricos e síndrome metabólica em diabetes tipo. Arquivos Brasileiros de Endocrinologia e Metabologia. Vol. 50. Num. 3. 2006. p. 450-455.
-Chen, S.; e colaboradores. Prevalence of abnormal serum liver enzymes in patients with type 2 diabetes mellitus: a cross-sectional study from China. Postgraduate Medicine. Vol. 128. Num. 8. 2016. p. 770-776.
-Chin, K. Y. The spice for joint inflammation: anti-inflammatory role of curcumin in treating osteoarthritis. Drug Design, Development and Therapy. Vol. 10. 2016. p. 3029-3042.
-Darabi, H.; e colaboradores. Adiponectin as a protective factor against the progression toward type 2 diabetes mellitus in postmenopausal women. Medicine. Vol. 94. Num. 33. 2015. p. e1347.
-Du, X.; e colaboradores. Inhibition of GAPDH activity. Journal of Clinical Investigation. Vol. 112. Num. 7. 2003. p. 1049-1057.
-Farhood, B.; e colaboradores. Curcumin as an anti-inflammatory agent: implications to radiotherapy and chemotherapy. Journal of Cellular Physiology. Vol. 234. Num. 5. 2018. p. 5728-5740.
-Farzaei, M. H.; e colaboradores. Curcumin in liver diseases: a systematic review of the cellular mechanisms of oxidative stress and clinical perspective. Nutrients. Vol. 10. Num. 855. 2018. p. 1-28.
-Ganjali, S.; e colaboradores. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. The Scientific World Journal. 2014. p. 1-6.
-Graier, W. F.; e colaboradores. Increased superoxide anion formation in endothelial cells during hyperglycemia: an adaptive response or initial step of vascular dysfunction? Diabetes Research and Clinical Practice. Vol. 45. Num. 2-3. 1999. p. 153-160.
-Guimarães, D. E. D.; e colaboradores. Adipocitocinas: uma nova visão do tecido adiposo. Revista de Nutrição. Vol. 20. Num. 5. 2007. p. 549-559.
-Hanley, A. J. G.; e colaboradores. Elevations in markers of liver injury and risk of type 2 diabetes. Diabetes. Vol. 53. Num. 10. 2004. p. 2623-2632.
-He, Y.; e colaboradores. Curcumin, inflammation, and chronic diseases: how are they linked? Molecules. Vol. 20. Num. 5. 2015. p. 9183-9213.
-Hills, C. E.; Brunskill, N. J.; Squires, P. E. C-peptide as a therapeutic tool in diabetic nephropathy. American Journal of Nephrology. Vol. 31. Num. 5. 2010. p. 389-397.
-Hodaei, H.; e colaboradores. The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes: a randomized, double-blind clinical trial. Diabetology & Metabolic Syndrome. Vol. 11. Num. 41. 2019. p. 1-8.
-Jiménez-Flores, L. M.; e colaboradores. A PPARγ, NF-κB and AMPK-Dependent mechanism may be involved in the beneficial effects of curcumin in the diabetic db/db mice liver. Molecules. Vol. 19. Num. 6. 2014. p. 8289-8302.
-Kalmár, T.; e colaboradores. Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus. Diabetes and Metabolism. Vol. 31. Num. 6. 2005. p. 574-580.
-Karthikeyan, A.; Senthil, N.; Min, T. Nanocurcumin: a promising candidate for therapeutic applications. Frontiers in Pharmacology. Vol. 11. 2020. p. 1-24.
-Keihanian, F.; e colaboradores. Curcumin, hemostasis, thrombosis, and coagulation. Journal of Cellular Physiology. Vol. 233. Num. 6. 2017. p. 4497-4511.
-Khandouzi, N.; e colaboradores. The effects of ginger on fasting blood sugar, hemoglobin A1c, apolipoprotein B, apolipoprotein A-I and malondialdehyde in type 2 diabetic patients. Iranian Journal of Pharmaceutical Research. Vol. 14. Num. 1. 2015. p. 131-140.
-Lima, L. M.; e colaboradores. Proteína C-reativa ultra-sensível em pacientes com diagnóstico de doença arterial coronariana estabelecido por angiografia. Jornal Brasileiro de Patologia e Medicina Laboratorial. Vol. 43. Num. 2. 2007. p. 83-86.
-Lopresti, A. L.; Drummond, P. D. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: a randomised, double-blind, placebo-controlled study. Journal of Affective Disorders. Vol. 207. 2017. p. 188-196.
-Mead, J. R.; Irvine, S. A.; Ramji, D. P. Lipoprotein lipase: structure, function, regulation, and role in disease. Journal of Molecular Medicine. Vol. 80. Num. 12. 2002. p. 753-769.
-Na, L.-X.; e colaboradores. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Molecular Nutrition & Food Research. Vol. 56. Num. 9. 2012. p. 1569-1577.
-Ndumele, C. E.; Pradhan, A. D.; Ridker, P. M. Interrelationships between inflammation, C-reactive protein, and insulin resistance. Journal of The Cardiometabolic Syndrome. Vol. 1. Num. 3. 2006. p. 190-196.
-Panahi, Y.; e colaboradores. Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. Inflammopharmacology. Vol. 25. Núm. 2016.+ 1. p. 25-31.
-Panahi, Y.; e colaboradores. Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. Complementary Therapies in Medicine. Vol. 33. 2017. p. 1-5.
-Panahi, Y.; e colaboradores. Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus: A randomized double-blind placebo-controlled trial. Drug Research. Vol. 68. Num. 7. 2018. p. 403-409.
-Parhofer, K. G. Interaction between glucose and lipid metabolism: More than diabetic dyslipidemia. Diabetes and Metabolism Journal. Vol. 39. Num. 5. 2015. p. 353-362.
-Pivari, F.; e colaboradores. Curcumin and type 2 diabetes mellitus: prevention and treatment. Nutrients. Vol. 11. Num. 8. 2019. p. 1837.
-Rabe, K.; e colaboradores. Adipokines and insulin resistance. Molecular Medicine. Vol. 14. Num. 11-12. 2008. p. 741-751.
-Rahimi, H. R.; e colaboradores. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomed. Vol. 6. Num. 5. 2016. p. 567-577.
-Reis, J. S.; e colaboradores. Estresse oxidativo: revisão da sinaliszação metabólica no diabetes tipo 1. Arquivos Brasileiros de Endocrinologia e Metabologia. Vol. 52. Num. 7. 2008. p. 1096-105.
-Ross, R. Atherosclerosis: in Inflammatory Disease. New England Journal of Medicine. Vol. 340. Num. 2. 1999. p. 115-126.
-Sahebkar, A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? BioFactors. Vol. 39. Num. 2. 2013a. p. 197-208.
-Sahebkar, A. Are curcuminoids effective C-Reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytotherapy Research. Vol. 28. Num. 5. 2013b. p. 633-642.
-Samarghandian, S.; e colaboradores. Anti-oxidative effects of curcumin on immobilization-induced oxidative stress in rat brain, liver and kidney. Biomedicine and Pharmacotherapy. Vol. 87. 2017. p. 223-229.
-Sánchez-Quesada, J. L.; Benítez, S.; Ordóñez-Llanos, J. Electronegative low-density lipoprotein. Current Opinion in Lipidology. Vol. 15. Num. 3. 2004. p. 329-335.
-Scheffel, R. S.; e colaboradores. Prevalence of micro and macroangiopatic chronic complications and their risk factors in the care of out patients with type 2 diabetes mellitus. Revista da Associação Médica Brasileira. Vol. 50. Num. 3. 2004. p. 263-267.
-Schlecht, I.; e colaboradores. Relations of visceral and abdominal subcutaneous adipose tissue, body mass index, and waist circumference to serum concentrations of parameters of chronic inflammation. Obesity Facts. Vol. 9. Num. 3. 2016. p. 144-157.
-Sevanian, A.; e colaboradores. Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arteriosclerosis, Thrombosis, and Vascular Biology. Vol. 16. Num. 6. 1996. p. 784-793.
-Shoba, G.; e colaboradores. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. Vol. 64. Num. 4. 1998. p. 353-356.
-Srinivasan, K. Black pepper and its pungent principle-piperine: A review of diverse physiological effects. Critical Reviews in Food Science and Nutrition. Vol. 47. Num. 8. 2007. p. 735-748.
-Sun, M.; e colaboradores. Advances in nanotechnology-based delivery systems for curcumin. Nanomedicine. Vol. 7. Num. 7. 2012. p. 1085-1100.
-Tomeh, M. A.; Hadianamrei, R.; Zhao, X. A review of curcumin and its derivatives as anticancer agents. International Journal of Molecular Sciences. Vol. 20. Num. 5. 2019. p. 1033.
-Wahren, J.; Larsson, C. C-peptide: new findings and therapeutic possibilities. Diabetes Research and Clinical Practice. Vol. 107. Num. 3. 2015. p. 309-319.
-Westerbacka, J.; e colaboradores. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: Implications for sex differences in markers of cardiovascular risk. Diabetologia. Vol. 47. Num. 8. 2004. p. 1360-1369.
-Wing, R. R.; e colaboradores. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. Vol. 34. Num. 7. 2011. p. 1481-1486.
-World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Genebra. World Health Organization. 2006.
-Wu, L.; Parhofer, K. G. Diabetic dyslipidemia. Metabolism: Clinical and Experimental. Vol. 63. Num. 12. 2014. p. 1469-1479.
-Yan, L.-J. Pathogenesis of Chronic Hyperglycemia: From Reductive Stress to Oxidative Stress. Journal of Diabetes Research. Vol. 2014. Num. 137919. 2014. p. 1-11.
-Yin, H.; e colaboradores. Curcumin Suppresses IL-1β Secretion and Prevents Inflammation through Inhibition of the NLRP3 Inflammasome. The Journal of Immunology. Vol. 200. Num. 8. 2018. p. 2835-2846.
-Yosten, G. L. C.; e colaboradores. Physiological effects and therapeutic potential of proinsulin C-peptide. American Journal of Physiology - Endocrinology and Metabolism. Vol. 307. Num. 11. 2014. p. 955–968.
-Younus, H. Therapeutic potentials of superoxide dismutase. International journal of health sciences. Vol. 12. Num. 3. 2018. p. 88-93.
-Zhang, D.; e colaboradores. Curcumin and diabetes: a systematic review. Evidence-Based Complementary and Alternative Medicine. Num. 1. 2013. p. 1-16.
Copyright (c) 2022 Joelma Maria da Silva, Veronyky Gomes da Silva, Rosimar Regina da Silva Araujo, Manoel Carlos Couto de Araujo, Patrícia Beltrão Lessa Constant, Flavia Escapini Fanchiotti
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Autores que publicam neste periódico concordam com os seguintes termos:
- Autores mantém os direitos autorais e concedem ao periódico o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Creative Commons Attribution License BY-NC que permitindo o compartilhamento do trabalho com reconhecimento da autoria do trabalho e publicação inicial neste periódico.
- Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada neste periódico (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial neste periódico.
- Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citaçao do trabalho publicado (Veja O Efeito do Acesso Livre).
